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Tobramycin-Induced Hepatotoxicity 
Sarah A Nisly, Shaunta’ M Ray, and Robert A Moye 
OBJECTIVE: To report a case of tobramycin-induced hepatotoxicity.                                                                                                       
CASE SUMMARY: A 20-year-old female was hospitalized for treatment of Pseudomonas aeruginosa bacteremia and osteomyelitis. 
Empiric intravenous antibiotic therapy with piperacillin/tazobactam, vancomycin, and ciprofloxacin was started, and based on the results 
of culture and sensitivity testing, was changed to intravenous ceftazidime and tobramycin 70 mg every 8 hours on hospital day 3. Liver 
enzyme levels then increased over days 3–6. Tests for hepatitis A, B, and C were all nonreactive, and HIV testing was negative. On day 
8, therapy was changed from ceftazidime to piperacillin/tazobactam and the tobramycin dose was increased to 100 mg every 8 hours. 
Due to a continued increase in total bilirubin, aspartate aminotransferase, and alanine aminotransferase, piperacillin/tazobactam was 
discontinued and aztreonam was started on day 10. All antibiotics were stopped on day 12 and the elevated liver parameters began to 
decrease. Aztreonam and ciprofloxacin were restarted on day 16, and most laboratory test results returned to baseline levels by day 19; 
total bilirubin and alkaline phosphatase decreased to lower than baseline values. 
DISCUSSION: This case illustrates a possible occurrence of tobramycin-induced hepatotoxicity. Liver enzymes rose when tobramycin 
therapy was initiated, markedly increased when the tobramycin dose was increased, then resolved upon discontinuation of therapy. Other 
medication-related causes were ruled out by temporal relationship or rechallenge (aztreonam). Use of the Naranjo probability scale 
indicated a possible relationship between hepatotoxicity and tobramycin therapy. Other adverse reaction scales specific for evaluation of 
drug-induced liver disease were also used. Both the Council for International Organizations of Medical Sciences and Maria and 
Victorino scales indicated a probable likelihood of tobramycin-induced hepatotoxicity. This patient was not rechallenged with 
tobramycin due to the highly suggestive timeline present, lack of specific symptoms, and unnecessary risk to the patient. 
CONCLUSIONS: Although no other case reports on this interaction have been published through October 9, 2007, historical data from 
tertiary sources reveal the possibility of aminoglycoside-induced hepatotoxicity; therefore, tobramycin induced hepatotoxicity cannot be 
ruled out in this patient. Clinicians should be aware of this adverse event. 
 Drug-related hepatotoxicity is an uncommon occurrence; its true incidence is difficult to determine.1 
Despite this, a significant number of drugs have been shown to cause hepatotoxicity. Because there are few 
clinical or laboratory manifestations that may specifically link liver injury with medication use, a temporal 
relationship between the initiation of a drug and liver injury and resolution of symptoms following withdrawal 
of the drug becomes extremely important.2 Tobramycin is more commonly associated with neurotoxicity 
(vestibular and auditory) and nephrotoxicity, although elevation in hepatic enzyme levels is reported as a 
possible adverse effect of its use.3 To date, no case reports of tobramycininduced hepatotoxicity have been 
published; however, historical data from tertiary sources reveal the possibility of aminoglycoside-induced 
hepatotoxicity.4 
We present a case of liver injury following administration of tobramycin. 
Case Report 
 A 20-year-old female was admitted with a chief symptom of pleuritic chest pain accompanied by fever 
and chills. Medical history included methicillin-resistant Staphylococcus aureus endocarditis and anxiety. 
Surgical history included open reduction and internal fixation of her right femur in 2005 with methicillin-
susceptible S. aureus osteomyelitis and cellulitis and a tricuspid valve replacement in 2004. The patient 
reported a history of illicit intravenous drug abuse prior to 2004 and rare alcohol use. Her home medications 
included paroxetine 40 mg daily, alprazolam 1 mg twice daily, metoclopramide 10 mg as needed, and 
hydrocodone/acetaminophen 7.5 mg/325 mg every 4–6 hours as needed. She had no known drug allergies. 
 Two blood cultures performed on samples obtained on the patient’s arrival were positive for 
Pseudomonas aeruginosa. Magnetic resonance imaging of the right lower extremity revealed some abnormal 
intensity in the right distal femur, correlating with osteomyelitis. Hepatitis A, B, and C serologic tests were 
nonreactive and HIV testing was negative. Other laboratory values are shown in Tables 1 and 2. 
 The patient’s home medications, except for metoclopramide, were continued on admission. Drug 
therapy during hospitalization included hydromorphone 0.5–1 mg, oxycodone/acetaminophen 5 mg/325 mg, 
promethazine 12.5 mg, docusate sodium 100 mg, and immediate-release oxycodone 5 mg. Empiric antibiotic 
therapy was started with intravenous piperacillin/tazobactam 3.375 g every 6 hours, intravenous vancomycin 
1g every 12 hours, and intravenous ciprofloxacin 400 mg every 12 hours. Upon the return of the susceptibility 
patterns, therapy was changed on hospital day 3 to intravenous ceftazidime 2 g every 8 hours and intravenous 
tobramycin 70 mg every 8 hours. Liver enzyme levels increased daily over the following 3 days (Figure 1). 
Total bilirubin and albumin decreased slightly during this time. Alkaline phosphatase initially declined, but 
began to rise on day 4. By day 6, there was a persistent elevation in liver enzymes and drug-induced 
hepatotoxicity was considered. Ceftazidime was considered the primary suspect for hepatotoxicity; it was 
discontinued on hospital day 8 and therapy with intravenous piperacillin/tazobactam 4.5 g every 6 hours was 
started. That same day, the tobramycin dose was increased to 100mg intravenously every 8 hours. Due to a 
continued increase in aspartate aminotransferase and alanine aminotransferase levels between days 8 and 10, 
piperacillin/tazobactam was discontinued and intravenous aztreonam 2g every 8 hours was started. Although 
total bilirubin initially decreased, it began to rise on day 8 and peaked at day 12, with alkaline phosphatase 
peaking on day 8.  
 Despite the discontinuation of piperacillin/tazobactam and ceftazidime, there was a continued 
dramatic elevation in liver enzymes; all antibiotics were stopped on day 12. On hospital day 14, total bilirubin 
and alkaline phosphatase began declining; on day 16, antibiotic therapy was restarted with intravenous 
aztreonam 2g every 8 hours and intravenous ciprofloxacin 400 mg every 8 hours. Liver enzymes continued to 
trend downward and all laboratory values had returned to baseline prior to the patient’s discharge on day 19. 
Total bilirubin and alkaline phosphatase decreased to lower than baseline values; ALT remained slightly above 
baseline. Oral ciprofloxacin 750 mg twice daily was continued for an additional 8 weeks. 
 
Table 1. Laboratory Values 
                                                    Day 
Parameter Admission 8 12 19 Reference 
Range 
Serum creatinine (mg/dL) 0.6 0.7 0.7 0.8 0.6–1.1 
BUN (mg/dL) 10 10 13 11 8–25 
White blood cell count (x 103/μL) 9.2 4.8 5.4 3.7 4.8–10.8 
Albumin (g/dL) 2.7 2.4 2.7 2.4 3.5–5 
Bilirubin (mg/dL)      
Total 
direct 
indirect 
3.2 
2.6 
0.6 
1.8 
NR 
NR 
4.9 
NR 
NR 
1.5 
1.1 
0.4 
0.2–1.0 
0–0.4 
0–1.1 
Alkaline phosphatase (units/L) 215 432 330 158 53–148 
AST (units/L) 52 332 970 42 5-34 
Amylase (units/L) 39 NR NR NR 25-125 
Lipase (units/L) 43 NR NR NR 8-78 
INR 1.23 NR 1.22 NR 0.8-1.4 
aPTT 33.8 NR 41 NR 21.4-31 
ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate aminotransferase; BUN = blood urea nitrogen; INR 
= international normalized ratio; NR = not reported. 
 
Discussion 
 Nephrotoxicity and neurotoxicity are the adverse events most commonly associated with 
aminoglycosides. This case illustrates a possible occurrence of tobramycin-induced hepatotoxicity. The patient 
presented with an active infection, bilirubinuria, and mildly elevated total bilirubin, alkaline phosphatase, and 
aspartate aminotransferase. 
 Although this patient’s medical history did not include liver dysfunction, laboratory values including 
total bilirubin, international normalized ratio, alkaline phosphatase, and albumin were abnormal upon 
admission, indicating underlying liver disease. Urobilinogen was also initially elevated; however, it returned to 
normal less than 12 hours after admission (a level of 2.0 is considered trace amounts by our institution’s 
laboratory). This decrease may have been due to the initiation of antibiotics. Alkaline phosphatase and 
aspartate aminotransferase were also mildly elevated upon admission. While this was also suggestive of liver 
dysfunction, the elevation in alkaline phosphatase may have been due to osteomyelitis. This patient denied a 
history of alcohol use but reported a distant history of intravenous cocaine abuse, which may have contributed 
to the underlying liver dysfunction. It would not be expected that this level of liver dysfunction would put her 
at a greater risk of experiencing drug-induced hepatotoxicity; however, females tend to have increased 
susceptibility.1 
 
 
 
 
 
 
 
 
 Upon initiation of empiric antibiotic therapy, liver enzymes remained stable. Figure 1 shows the 
strong correlation between the initiation of tobramycin and the elevation of liver enzyme levels. This persistent 
elevation, despite discontinuation of antibiotics more commonly recognized as offenders, such as ceftazidime 
and piperacillin/tazobactam, reinforces the likelihood of tobramycin-induced hepatotoxicity. Both ceftazidime 
and piperacillin/tazobactam were discontinued 3–5 days before the spike in liver enzymes, and 
piperacillin/tazobactam was restarted after persistent elevation of liver enzymes. Given the short halflives of 
these drugs, there is a low probability of a delayed hepatotoxicity reaction. Other antibiotics used were 
excluded by the same timeline, or in the instance of aztreonam, by rechallenge. 
Table 2. Urinalysis 
Laboratory 
Value 
Day 1 
(1045) 
Reference 
Range 
Appearance 
Color 
Specific gravity 
Urine 
pH 
protein 
glucose 
Ketones 
Nitrites 
Urobilinogen (mg/dL) 
Bile 
WBC esterase 
clear 
dark yellow 
1.024 
 
6.0 
30 
negative 
negative 
negative 
4.0 
moderate 
negative 
 
 
1.005–1.030 
 
4.5–7.0 
negative 
negative 
negative 
negative 
none—trace 
negative 
negative 
WBC = white blood cell. 
 Nondrug causes of hepatotoxicity were evaluated throughout the patient’s hospital stay. An ultrasound 
of the right upper quadrant, performed on admission, revealed only nonspecific gallbladder thickening. A 
follow-up computed tomography scan on hospital day 11 showed no specific findings. Viral hepatitis was 
excluded by negative serologic tests for hepatitis A, B, and C, along with a negative HIV panel. However, 
given the time lag between time of infection and positive testing, it is possible that the patient may have been 
infected recently. 
 Evaluation of the case, using the Naranjo probability scale, indicated a possible relationship between 
hepatotoxicity and tobramycin therapy in our patient.5 Liver enzymes increased when tobramycin was initiated 
and resolved upon discontinuation of therapy. Additionally, when the tobramycin dose was increased, 
subsequent liver enzyme levels were markedly increased. Tobramycin concentrations attained during 
admission were never supratherapeutic. Other medication-related causes were ruled out, as the timeline 
associated with their administration did not correlate with the rise in liver enzymes and the patient reported 
taking all home medications as prescribed prior to admission. 
 Although the Naranjo scale is the most commonly used method of calculating adverse event 
probability, other methods specific for the evaluation of drug-induced liver disease are available. The accuracy 
of the Naranjo probability scale, when used to evaluate drug-induced liver disease, was questioned by Garcia 
Cortes et al.6 They discussed the discrepancy found when evaluating cases of drug-induced liver disease on the 
Naranjo scale versus the Council for International Organizations of Medical Sciences (CIOMS)7 or the Maria 
and Victorino (M&V)8 scales. Depending on the scale used, the categorized likelihood of drug-induced 
reaction can change. When evaluated on the CIOMS scale, our case had a score of 8, corresponding with a 
probable likelihood of tobramycin-induced hepatotoxicity; when assessed on the M&V scale, our case scored 
15, also corresponding with a probable likelihood. 
 Our patient was not rechallenged with tobramycin due to the highly suggestive timeline present, lack 
of specific symptoms, and unnecessary risk. The patient did not have symptoms common with liver injuries, 
such as rash or eosinophilia; however, she was febrile at various times throughout admission. These fevers 
were likely due to osteomyelitis and bacteremia. 
 The mechanism of hepatic injury with tobramycin is unclear. Currently, no dosage adjustments are 
necessary for hepatic insufficiency and the primary route of elimination is renal (60–85%). In addition to renal 
clearance, other routes of elimination include feces (35–79%) and bile (minimal amount).9 
 
Figure 1 Liver function enzymes in relation to antibiotic administration. Alk Phos = alkaline phosphatase; ALT = alanine 
aminotransferase; AST = aspartate 
 
Conclusions 
 
 Although no other case reports on this interaction have been published, practitioners cannot rule out 
the possibility of tobramycin-induced hepatotoxicity. Early recognition and dose changes or drug withdrawal 
may prevent unnecessary intervention or permanent damage. 
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